Sullivan Lara's Form 4 filing
Pyxis Oncology, Inc. (PYXS) · filed Sep 18, 2023
- Accession no.
- 0001209191-23-049826
- Filed
- Sep 18, 2023
- Trade date
- Sep 14-18, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $18.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sullivan LaraCIK 0001769457 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2023 | Common Stock | SSaleDisposed | −100 | $2.25 | −$225 | 2,412,423 | Direct | |
| Sep 18, 2023 | Common Stock | SSaleDisposed | −8,541 | $2.10 | −$17,936.1 | 2,403,882 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.